Our goal is to be the leading global biopharmaceutical company focused on the innovative treatment of women’s health and endocrine diseases in areas of high unmet medical need, and improve the lives of millions of patients suffering from these diseases.
2000 Sierra Point Parkway
Brisbane, CA 94005
Latest Company News
- Myovant Sciences Ltd. (MYOV) Receives $20.00 Average Price Target from Brokerages
- Myovant Sciences (MYOV) and Its Rivals Head to Head Contrast
- Myovant Sciences (MYOV) Getting Somewhat Positive Media Coverage, Report Finds
- Session Watch: Minus DI Above Plus DI for Myovant Sciences Ltd (MYOV)
- Brokerages Anticipate Myovant Sciences Ltd. (MYOV) Will Post Earnings of -$0 …
- Myovant Sciences Ltd. (NASDAQ:MYOV) Given “Buy” Rating at Robert W. Baird
- Myovant Sciences Provides Corporate Update and Reports Financial Results for …
- Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With …
- Myovant Sciences Ltd. Announces Pricing of Initial Public Offering
- Myovant Sciences Ltd.